Clinical trials: Fat; Liver
Non-Alcoholic Fatty Liver Disease
Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH)
The primary objective of this study is to evaluate to provide evidence to establish tightly defined cut-offs to identify patients for NASH clinical trial inclusion using cT1 and/or PDFF.
- Trial name
- NCT04341246
- Testing
- LiverMultiscan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Perspectum
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Psoriatic Arthritis (PsA), Liver Fibrosis
Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments
Psoriatic arthritis (PsA) is an inflammatory joint disease that can also affect the liver. Some medications used to treat PsA, such as biological agents (TNF-alpha inhibitors and IL-17 inhibitors), may influence liver health over…
- Conditions
- Psoriatic Arthritis (PsA), Liver Fibrosis, Liver Diseases
- Trial name
- FIB-4 PsA (NCT06918886)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Bezmialem Vakif University
Chronic Liver Disease, Steatohepatitis
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
The purpose of this study is to evaluate non-invasive parameters for staging and grading of chronic hepatopathy in comparison to liver biopsy.
- Conditions
- Chronic Liver Disease, Steatohepatitis, Fibrosis
- Trial name
- NCT01246388
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Tischendorf, Jens, M.D.
Non-alcoholic Fatty Liver Disease
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and…
- Trial name
- ZENITH-1 (NCT07221227)
- Testing
- Efimosfermin alfa
- Where
- 91 sites in United States, Australia and 7 more
- Volunteers
- 1,200 people
- Sponsor
- GlaxoSmithKline
Fibrosis, Liver
Screening for Chronic Liver Diseases in General Population
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
- Trial name
- HEPGEN (NCT06366425)
- Testing
- Blood sample then fibroscan
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Non-Alcoholic Fatty Liver Disease, Insulin Resistance
Effect of PNPLA3, TM6SF2 and MBOAT7 Genetic Variants on Non-alcoholic Fatty Liver Disease Therapeutic Outcome.
Patatin-like phospholipase domain-containing protein-3 (PNPLA3), the transmembrane 6 superfamily member 2 protein (TM6SF2) and membrane bound O-acyltransferase domain containing 7 (MBOAT7) genes are involved in non-alcoholic…
- Trial name
- NCT04640324
- Testing
- Nutraceutical therapy
- Where
- 3 sites in Italy
- Volunteers
- 92 people
- Sponsor
- University of Campania Luigi Vanvitelli
Non-alcoholic Fatty Liver Disease
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
- Trial name
- ZENITH-2 (NCT07221188)
- Testing
- Efimosfermin Alfa
- Where
- 66 sites in United States, Australia and 6 more
- Volunteers
- 1,250 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
- Trial name
- NCT05053165
- Testing
- LB-P6, LB-P8
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- LISCure Biosciences
Chronic HCV Infection, Nonalcoholic Steatohepatitis
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
In the presented project, the role of heme oxygenase 1 and 2 in the procesess associated with fibroproduction in the chronic HCV infection will be studied.
- Trial name
- NCT00842205
- Testing
- pegylated interferon, Ribavarin
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Charles University, Czech Republic
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with…
- Trial name
- NCT06007651
- Testing
- LY3885125
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Fatty Liver, Nonalcoholic
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Study question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective…
- Trial name
- NCT06117137
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease
Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) will provide accurate quantitative measurements that can be used to stage liver fibrosis in patients with chronic liver disease. 1.
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV)
- Trial name
- NCT01747772
- Testing
- Shear Wave Sonoelastography
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
MLCT Oil for Fatty Liver - PASS Trial
The main objective of this randomised pilot study is to explore the relative efficacy of dietary MLCT oil versus LCT oil (corn oil) in augmenting therapy of overweight and obese NAFLD patients with at least a 1-stage reversal…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, NAFLD
- Trial name
- PASS (NCT05217745)
- Testing
- MLCT Oil, LCT Oil (Corn Oil)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Non Alcoholic Steatohepatitis
Coffee Consumption and NASH in the French Population.
The aim of our study is to evaluate the effect of coffee consumption on the risk of severe liver fibrosis in French patients with NASH.
- Trial name
- COCANASH (NCT03432377)
- Where
- 16 sites in France
- Volunteers
- 107 people
- Sponsor
- Versailles Hospital
NAFLD - Nonalcoholic Fatty Liver Disease
Hepatic and Cardiac Metabolic Flexibility in Obese With NAFLD.
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT03583437
- Testing
- Exercise
- Where
- Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
NAFLD
Transient Elastography of the Liver ( Fibroscan ) and Bariatric Surgery
To evaluate the effect of Bariatric surgery on the extent of liver fat and liver fibrosis and on different metabolic parameters in patients undergoing sleeve gastrectomy surgery.
- Trial name
- NCT02122263
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Obesity, Fatty Liver
Impact of Bariatric Surgery on the Evolution of Nonalcoholic Fatty Liver Disease: a Comparative Clinical Trial Between Sleeve Gastrectomy and Gastric Bypass
Aim: To compare prospectively two bariatric surgery techniques: sleeve gastrectomy (SG) vs gastric bypass (GB) in the evolution of nonalcoholic fatty liver disease (NAFLD) measured by the transient elastography in the first year.
- Trial name
- NCT02394353
- Testing
- Transient hepatic elastography
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Brazil
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Diabetes Mellitus, Hypertension
- Trial name
- OCES-2 (NCT06694012)
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- Osaka Metropolitan University
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity.
- Trial name
- QUS in NASH (NCT03572465)
- Testing
- Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.